ArticleInternational journal for parasitology. Drugs and drug resistance2012
Recent highlights in anti-protozoan drug development and resistance research.
Article in International journal for parasitology. Drugs and drug resistance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South.Acta parasitologica · 2023Article
- Preclinical Studies and Drug Combination of Low-Cost Molecules for Chagas Disease.Pharmaceuticals (Basel, Switzerland) · 2022Article
- [Malarial antigens in the era of mRNA vaccines].Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde · 2022Review
- Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease.Parasites & vectors · 2021Article
- Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells.Journal of bioenergetics and biomembranes · 2018Article
- Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.Parasitology · 2018Review
- Recent advances inF1000Research · 2016Review
- Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification.Organic & biomolecular chemistry · 2014Review
- Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica.Antimicrobial agents and chemotherapy · 2014Article
- Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
This article summarizes the highlights of research presented in January, 2012, at the Keystone Symposium on "Drug Discovery for Protozoan Parasites" held in Santa Fe, New Mexico. This symposium which convenes approximately every 2 years provides a forum for leading investigators around the world to present data covering basic sciences to clinical trials relating to anti-protozoan drug development and drug resistance. Many talks focused on malaria, but other protozoan diseases receiving attention included African sleeping sickness, Chagas disease, leishmaniasis, cryptosporidiosis, and amoebiasis. The new research, most of it unpublished, provided insights into the latest developments in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.